XML 42 R20.htm IDEA: XBRL DOCUMENT
v3.22.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-based Payment Arrangement [Abstract] |
Stock-Based Compensation | Stock-Based Compensation 2018 Stock Plan On November 27, 2018, Legacy Xos’ board of directors and stockholders adopted the 2018 Stock Plan. There are no shares available for issuance under the 2018 Stock Plan, however, the 2018 Stock Plan continues to govern the terms and conditions of the outstanding awards granted under the 2018 Stock Plan. ‘ Options As of December 31, 2021 there were 1,838,759 Options outstanding under the 2018 Stock Plan. The amount and terms of option grants were determined by the board of directors of Legacy Xos. The options granted under the 2018 Stock Plan generally expire within 10 years from the date of grant and generally vest over four years, at the rate of 25% on the first anniversary of the date of grant and ratably on a monthly basis over the remaining 36-month pe riod thereafter based on continued service. Stock option activity for the year ended December 31, 2021 consisted of the following:
| Options |  | Weighted Average Fair Value |  | Weighted Average Exercise Price |  | Weighted Average Remaining Years |  | Intrinsic Value
December 31, 2020 — Options outstanding | 2,671,738 |  |  | $ | 0.01 |  |  | $ | 0.02 |  |  | 9.24 |  | $ | 27,000 |
Granted | — |  |  | — |  |  | — |  |  |  |  |
Exercised | 561,413 |  |  | 0.02 |  |  | 0.02 |  |  |  |  |
Forfeited | 271,566 |  |  | 0.03 |  |  | 0.04 |  |  |  |  |
December 31, 2021 — Options outstanding | 1,838,759 |  |  | $ | 0.02 |  |  | $ | 0.02 |  |  | 8.22 |  | $ | 5,756,797 |
December 31, 2021 — Options vested and exercisable | 482,868 |  |  | $ | 0.02 |  |  | $ | 0.02 |  |  | 7.99 |  | $ | 1,511,159 |
Aggregate intrinsic value represents the difference between the exercise price of the options and the fair value of the Company’s common stock. The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 were approxi mately $5.8 million a nd $4,000, respectively. The Company estimates the fair value of options utilizing the Black-Scholes option pricing model, which is dependent upon several variables, including expected option term, expected volatility of the Company's share price over the expected term, expected risk-free rate and expected dividend yield rate. There were no option grants during the year ended December 31, 2021. Assumptions utilized by the Company to record compensation expense during the year ended December 31, 2020 consisted of the following:
|  | December 31, 2020
Expected dividend yield |  | 0%
Stock price volatility |  | 55% – 80%
Expected term |  | 6 to 7 years
Risk-free interest rate |  | 0.60% – 3.06%
Grant-date fair value |  | $0.02 – $0.05
2021 Equity Plan On August 19, 2021 the Company’s stockholders approved the 2021 Equity Plan, which was ratified by the Company’s board of directors on August 20, 2021. The 2021 Equity Plan provides for the grant of incentive stock options (“ISOs”), within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) to employees, including employees of any parent or subsidiary, and for the grant of no statutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, RSUs, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of Xos’ affiliates. As of December 31, 2021, there were 16,421,919 shares of Common Stock available for issuance under the 2021 Equity Plan. RSU activity for the year ended December 31, 2021 consisted of the following:
| RSU’s |  | Weighted Average Grant Date Fair Value |  | Weighted Average Fair Value
December 31, 2020 — RSU outstanding | — |  |  | — |  |  | $ | — |
Granted | 2,150,923 |  |  | 3.56 |  |  | 7,652,927 |
Vested | 285,603 |  |  | 3.31 |  |  | 944,579 |
Forfeited | 20,500 |  |  | 3.31 |  |  | 64,130 |
December 31, 2021 — RSU outstanding | 1,844,820 |  |  | 3.60 |  |  | $ | 5,811,183 |
The Company recognized stock-based compensation expense in the consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2021 and 2020 totaling approximate ly $1.7 million and $15,000, respectively, which consisted of the following (in thousands):
|  | December 31, 2021 |  | December 31, 2020
Research and development |  | $ | 361 |  |  | $ | — |
Sales and marketing |  | 108 |  |  | — |
General and administrative |  | 1,189 |  |  | 15 |
Total |  | $ | 1,658 |  |  | $ | 15 |
The unamortized stock-based compensation was $6.4 million as of December 31, 2021, and weighted average remaining amortization period as of December 31, 2021 was 2.98 years. The aggregate fair value of RSU’s that vested w as $944,579 during the year ended December 31, 2021.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration